- Home
- PGHL vs CRDF Comparison
PGHL vs CRDF Comparison
Compare PGHL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGHL
- CRDF
- Stock Information
- Founded
- PGHL 2018
- CRDF 1999
- Country
- PGHL Hong Kong
- CRDF United States
- Employees
- PGHL N/A
- CRDF N/A
- Industry
- PGHL
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGHL
- CRDF Health Care
- Exchange
- PGHL NYSE
- CRDF Nasdaq
- Market Cap
- PGHL 12.3M
- CRDF 196.2M
- IPO Year
- PGHL 2024
- CRDF N/A
- Fundamental
- Price
- PGHL $0.45
- CRDF $2.63
- Analyst Decision
- PGHL
- CRDF Strong Buy
- Analyst Count
- PGHL 0
- CRDF 4
- Target Price
- PGHL N/A
- CRDF $12.00
- AVG Volume (30 Days)
- PGHL 154.0K
- CRDF 1.1M
- Earning Date
- PGHL 05-21-2025
- CRDF 05-20-2025
- Dividend Yield
- PGHL N/A
- CRDF N/A
- EPS Growth
- PGHL N/A
- CRDF N/A
- EPS
- PGHL N/A
- CRDF N/A
- Revenue
- PGHL $17,166,534.00
- CRDF $683,000.00
- Revenue This Year
- PGHL N/A
- CRDF N/A
- Revenue Next Year
- PGHL N/A
- CRDF N/A
- P/E Ratio
- PGHL $13.97
- CRDF N/A
- Revenue Growth
- PGHL 56.11
- CRDF 39.96
- 52 Week Low
- PGHL $0.37
- CRDF $2.01
- 52 Week High
- PGHL $107.36
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PGHL N/A
- CRDF 41.22
- Support Level
- PGHL N/A
- CRDF $2.42
- Resistance Level
- PGHL N/A
- CRDF $2.87
- Average True Range (ATR)
- PGHL 0.00
- CRDF 0.18
- MACD
- PGHL 0.00
- CRDF 0.01
- Stochastic Oscillator
- PGHL 0.00
- CRDF 24.42
About PGHL PRIMEGA GROUP HOLDINGS LIMITED
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.